Shares | Nanologica

NUMBER OF SHARES AND VOTES IN NANOLOGICA AB (PUBL)

30 April, 2026

The number of registered shares and votes in Nanologica AB has changed during the month of April as a result of registration of issues resolved by the Board of Directors on 30 January 2026 and approved by the subsequent Extraordinary General Meeting on 4 March 2026. All parts of the issues are now registered. This means that the number of shares in Nanologica during April has increased by 208,796,242 shares from 119,973,600 to 328,769,842 shares

ANTAL AKTIER OCH RÖSTER I NANOLOGICA AB (PUBL)

30 April, 2026

Antalet registrerade aktier och röster i Nanologica AB har under april månad ändrats till följd av registrering av emissioner som styrelsen beslutade om den 30 januari 2026 och som godkändes på efterföljande extra bolagsstämma den 4 mars 2026. Samtliga delar av emissionerna är nu registrerade. Det innebär att antalet aktier i Nanologica under april har ökat med 208 796 242 aktier från 119 973 600 till 328 769 842 aktier och att aktiekapitalet har ökat med 10 648 608,342 SEK

ANTAL AKTIER OCH RÖSTER I NANOLOGICA AB (PUBL)

31 March, 2026

Antalet registrerade aktier och röster i Nanologica AB har under mars månad ändrats till följd av de riktade emissioner som styrelsen beslutade om den 30 januari 2026 och som godkändes på efterföljande extra bolagsstämma den 4 mars 2026 (de ”Riktade Emissionerna”). De Riktade Emissionerna omfattade totalt 34 203 780 aktier, varav 31 603 780 aktier har delregistrerats under mars månad. De resterande 2 600 000 aktierna förväntas att registreras i samband bolagets företrädesemission. Det innebär att antalet aktier i Nanologica

NUMBER OF SHARES AND VOTES IN NANOLOGICA AB (PUBL)

31 March, 2026

The number of registered shares and votes in Nanologica AB has changed during the month of March as a result of the directed share issues resolved by the board of directors on 30 January 2026 and approved at the subsequent extraordinary general meeting on 4 March 2026 (the "Directed Issues"). The Directed Issues comprised a total of 34,203,780 shares, of which 31,603,780 shares have been partially registered during the month of March. The remaining 2,600,000

Nanologica Publishes Information Document Regarding Directed Share Issues and Rights Issue

6 March, 2026

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION REQUIRES A PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE CONTRAVENES APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH

Nanologica offentliggör informationsdokument avseende riktade nyemissioner och företrädesemission

6 March, 2026

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN DISTRIBUTION KRÄVER PROSPEKT, REGISTRERING ELLER ANDRA ÅTGÄRDER UTÖVER DE SOM FÖLJER AV SVENSK RÄTT, ÄR FÖRBJUDEN, ELLER ANNARS STRIDER MOT TILLÄMPLIGA REGLER I SÅDAN JURISDIKTION ELLER INTE KAN SKE UTAN TILLÄMPNING AV UNDANTAG FRÅN SÅDAN ÅTGÄRD. SE AVSNITTET "VIKTIG INFORMATION" I SLUTET

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.